97 related articles for article (PubMed ID: 7656227)
21. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
Pogribny IP; James SJ
Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
[TBL] [Abstract][Full Text] [Related]
22. Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Zhuang S; Söderkvist P
Mutat Res; 2000 Jul; 452(1):19-26. PubMed ID: 10894886
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the c-myc, K-ras and p53 genes in methylcholanthrene-induced mouse sarcomas.
Watanabe H; Shimokado K; Asahara T; Dohi K; Niwa O
Jpn J Cancer Res; 1999 Jan; 90(1):40-7. PubMed ID: 10076563
[TBL] [Abstract][Full Text] [Related]
24. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.
Murakami Y; Hayashi K; Hirohashi S; Sekiya T
Cancer Res; 1991 Oct; 51(20):5520-5. PubMed ID: 1655254
[TBL] [Abstract][Full Text] [Related]
25. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
26. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
Anna CH; Sills RC; Foley JF; Stockton PS; Ton TV; Devereux TR
Cancer Res; 2000 Jun; 60(11):2864-8. PubMed ID: 10850429
[TBL] [Abstract][Full Text] [Related]
27. [A molecular pathological study of p53 gene in hepatocellular carcinoma].
Zhao P
Zhonghua Bing Li Xue Za Zhi; 1993 Feb; 22(1):16-8. PubMed ID: 8101139
[TBL] [Abstract][Full Text] [Related]
28. Replication error phenotype and p53 gene mutation in lymphomas of mucosa-associated lymphoid tissue.
Peng H; Chen G; Du M; Singh N; Isaacson PG; Pan L
Am J Pathol; 1996 Feb; 148(2):643-8. PubMed ID: 8579126
[TBL] [Abstract][Full Text] [Related]
29. p53 alterations in chemically induced hamster cheek-pouch lesions.
Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
[TBL] [Abstract][Full Text] [Related]
30. p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons.
Kazachkov Y; Khaoustov V; Yoffe B; Solomon H; Klintmalm GB; Tabor E
Carcinogenesis; 1996 Oct; 17(10):2207-12. PubMed ID: 8895490
[TBL] [Abstract][Full Text] [Related]
31. p53 gene mutation pattern in rat liver tumors induced by vinyl chloride.
Barbin A; Froment O; Boivin S; Marion MJ; Belpoggi F; Maltoni C; Montesano R
Cancer Res; 1997 May; 57(9):1695-8. PubMed ID: 9135010
[TBL] [Abstract][Full Text] [Related]
32. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Machtens S; Werner M; Jonas U
Cancer; 1996 Nov; 78(9):1958-66. PubMed ID: 8909317
[TBL] [Abstract][Full Text] [Related]
33. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Hsu IC; Tokiwa T; Bennett W; Metcalf RA; Welsh JA; Sun T; Harris CC
Carcinogenesis; 1993 May; 14(5):987-92. PubMed ID: 8389256
[TBL] [Abstract][Full Text] [Related]
34. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
36. Mutation and expression of the p53 gene during chemical hepatocarcinogenesis in F344 rats.
Fu Y; Deng W; Kawarada Y; Kawagoe M; Ma YZ; Li X; Guo N; Kameda T; Terada K; Sugiyama T
Biochim Biophys Acta; 2003 Jul; 1628(1):40-9. PubMed ID: 12850271
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
38. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
[TBL] [Abstract][Full Text] [Related]
39. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
40. Absence of p53 mutations in malignant mesotheliomas.
Mor O; Yaron P; Huszar M; Yellin A; Jakobovitz O; Brok-Simoni F; Rechavi G; Reichert N
Am J Respir Cell Mol Biol; 1997 Jan; 16(1):9-13. PubMed ID: 8998073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
